- 17% growth in
January 2021for new TYMLOS® patients vs. previous 4 month trailing average
- Histomorphometry study published:
Journal of Bone & Mineral Research in January 2021
- Cardiovascular safety study published:
Journal of Clinical Endocrinology & Metabolismin November 2020 Japan: with our partner – Teijin – the regulatory timelines remain on schedule Canada: with our recently announced partner – Paladin Labs– regulatory activity on schedule
- Abaloparatide wearABLe study (Transdermal System) and the ATOM study (Osteoporotic Men at High Risk of Fracture) remain on schedule
New Patient Growth: TYMLOS in the U.S. market
“Our focus on postmenopausal osteoporotic-related fracture patients continues to gain traction,” commented
Radius added 1,692 new patients in the month of January. This represents a 17% increase from the previous four-month trailing average. New patients are defined as those patients who have been prescribed TYMLOS and subsequently filled their first prescription.
“Recently published data continues to reinforce the depth, breadth and overall quality of the abaloparatide molecule,” commented
- “Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women with Osteoporosis”
Dempster et al, JBMR
In an open-label, single-arm study conducted over 90 days in 23 postmenopausal women with osteoporosis:
- Abaloparatide demonstrated increases in bone formation across all four bone envelopes (cancellous, endocortical, intracortical, and periosteal envelopes) in iliac bone biopsies
- Increases in the bone formation were associated with stimulation of both modeling-based and remodeling-based formation
- Histomorphometric changes are correlated with the serum biomarker response to abaloparatide, which is associated with increases in bone mass at cortical and trabecular sites
- “Cardiovascular Safety of Abaloparatide in Postmenopausal Women with Osteoporosis: Analysis From the ACTIVE Phase 3 Trial”
Cosman et al, JCEM
In a post-hoc analysis:
- Treatment with abaloparatide and teriparatide resulted in a transient increase in heart rate and a small decrease in one-hour post dose blood pressure, however, these changes were not associated with an increase in serious cardiac adverse events evaluated in ACTIVE, major adverse cardiac events (MACE), or heart failure (HF)
- Time to first incidence of MACE + HF was longer with abaloparatide and teriparatide vs. placebo
“We continue to make progress on expanding, strengthening and broadening the abaloparatide molecule,” commented
Shah added that, “There is currently ongoing regulatory activity in the
About TYMLOS® (abaloparatide) Injection
TYMLOS® (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
IMPORTANT SAFETY INFORMATION
WARNING: RISK OF OSTEOSARCOMA
- Abaloparatide caused a dose-dependent increase in the incidence of osteosarcoma (a malignant bone tumor) in male and female rats. The effect was observed at systemic exposures to abaloparatide ranging from 4 to 28 times the exposure in humans receiving the 80-mcg dose. It is unknown if TYMLOS will cause osteosarcoma in humans.
- The use of TYMLOS is not recommended in patients at increased risk of osteosarcoma including those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, or prior external beam or implant radiation therapy involving the skeleton.
- Cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient's lifetime is not recommended.
Orthostatic Hypotension: Orthostatic hypotension may occur with TYMLOS, typically within 4 hours of injection. Associated symptoms may include dizziness, palpitations, tachycardia or nausea, and may resolve by having the patient lie down. For the first several doses, TYMLOS should be administered where the patient can sit or lie down if necessary.
Hypercalcemia: TYMLOS may cause hypercalcemia. TYMLOS is not recommended in patients with pre-existing hypercalcemia or in patients who have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, because of the possibility of exacerbating hypercalcemia.
Hypercalciuria and Urolithiasis: TYMLOS may cause hypercalciuria. It is unknown whether TYMLOS may exacerbate urolithiasis in patients with active or a history of urolithiasis. If active urolithiasis or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered.
Adverse Reactions: The most common adverse reactions (incidence ≥2%) are hypercalciuria, dizziness, nausea, headache, palpitations, fatigue, upper abdominal pain and vertigo.
INDICATIONS AND USAGE
TYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures.
Limitations of Use
Because of the unknown relevance of the rodent osteosarcoma findings to humans, cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient's lifetime is not recommended.
For the TYMLOS prescribing information, including Boxed Warning, please visit www.tymlospi.com.
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine and other therapeutics. For more information, please visit www.radiuspharm.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including those related to the Company’s
Investor Relations Contact:
Source: Radius Health Inc.